ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

304
Analysis
Health CareSouth Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
Refresh
05 Oct 2017 22:59

Foreign Investors Vs. Local Institutions in Korean Stock Market - Who Is Right?

Last month, foreign investors went on a buying spree in the Korea's second largest stock market, KOSDAQ. In contrast, they went on a selling spree...

Logo
1k Views
Share
04 Oct 2017 00:25

Biosimilar Battlefield: U.S. Humira Pushed to 2023

We are updating our market model to reflect the patent litigation settlement between Amgen Inc (AMGN US) and Abbvie Inc (ABBV US) , the...

Share
bearishCelltrion Inc
24 Sep 2017 03:44

Biosimilar Battlefield: Celltrion Forecasts

This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...

Share
13 Sep 2017 22:59

Biosimilar Battlefield: Samsung Bioepis Forecast

This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...

Share
08 Sep 2017 10:35

Surveying The Biosimilar Battlefield

The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS)  and...

Share
x